Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2018 Oct;10(10):E739-E743.
doi: 10.21037/jtd.2018.09.101.

A combined subtype of small cell lung cancer and adenocarcinoma with epidermal growth factor receptor (EGFR) mutation responds to EGFR tyrosine kinase inhibitors

Yong Zhang  1 , Ling Ye  1 , Huijun Zhang  1 , Xuehua Chen  1 , Haiying Ji  1 , Gang Chen  1 , Lu Zhang  2 , Tengfei Zhang  2 , Meiling Jin  1
Affiliations
Case Reports

A combined subtype of small cell lung cancer and adenocarcinoma with epidermal growth factor receptor (EGFR) mutation responds to EGFR tyrosine kinase inhibitors

Yong Zhang et al. J Thorac Dis. 2018 Oct.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: The authors have no conflicts of interest to declare.

Figures

Figure 1
Figure 1
Representative morphology of the mixture of small cell carcinoma and adenocarcinoma (hematoxylin-eosin staining, 20×). (A) Morphology of small cell carcinoma component; (B) morphology of adenocarcinoma component.
Figure 2
Figure 2
The IGV screenshot demonstrates the reads from next-generation sequencing of EGFR A750_I759delinsGEG gene alteration.
Figure 3
Figure 3
Clinical response of tumor lesions to EGFR-TKI treatment revealed by chest computed tomography (CT) scans. EGFR, epidermal growth factor receptor; TKI, tyrosine kinase inhibitor.
Figure 4
Figure 4
Dynamic monitoring of EGFR A750_I759delinsGEG allelic fraction during the treatment of EGFR-TKIs. Y-axis represents allelic fraction and X-axis represents treatment milestones. EGFR, epidermal growth factor receptor; TKI, tyrosine kinase inhibitor.
See this image and copyright information in PMC

References

    1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin 2018;68:7-30. 10.3322/caac.21442 - DOI - PubMed
    1. Gridelli C, Rossi A, Carbone DP, et al. Non-small-cell lung cancer. Nat Rev Dis Primers 2015;1:15009. 10.1038/nrdp.2015.9 - DOI - PubMed
    1. Engelman JA, Janne PA. Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Clin Cancer Res 2008;14:2895-9. 10.1158/1078-0432.CCR-07-2248 - DOI - PubMed
    1. Shigematsu H, Lin L, Takahashi T, et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 2005;97:339-46. 10.1093/jnci/dji055 - DOI - PubMed
    1. Kazandjian D, Blumenthal GM, Yuan W, et al. FDA Approval of Gefitinib for the Treatment of Patients with Metastatic EGFR Mutation-Positive Non-Small Cell Lung Cancer. Clin Cancer Res 2016;22:1307-12. 10.1158/1078-0432.CCR-15-2266 - DOI - PubMed

Publication types

LinkOut - more resources